Gabapentin Tablet, Film Coated
Product Images NDC 16714-330

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 16714-330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Gabapentin Fig1)

An instructional formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. The formula assists in estimating kidney function.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores on the vertical axis (0 to 10) and weeks on the horizontal axis (baseline to week 8). Two lines represent placebo and gabapentin 3600 mg/day, with gabapentin showing a decreasing trend in mean pain scores over 8 weeks, compared to a relatively stable trend for placebo. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

Line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks starting from baseline. The x-axis represents weeks, and the y-axis represents mean pain scores from 0 to 10. The graph compares three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, with a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar chart showing the proportion of responders achieving at least 50% reduction in pain score in controlled PHN studies. It compares placebo (PBO) groups with Gabapentin (GBP) doses of 1800 mg, 2400 mg, and 3600 mg across two studies, indicating higher response rates in GBP groups with statistical significance levels noted.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot chart showing the responder rate difference (%) from placebo for Gabapentin by daily dose (600 mg, 1200 mg, 1800 mg) across three studies (a, b, and c) in patients 12 years or older with partial seizures. The vertical axis represents the percentage difference, and the horizontal axis shows daily dose in milligrams.*

FDA Label Image

Package Label-principal Display Panel – 600 mg (100 Tablets Bottle) (Gabapentin Fig6)

Label for Gabapentin Tablets, USP 600 mg film-coated oral tablets, supplied in a bottle of 100 tablets. Manufactured for NorthStar Rx LLC, Memphis, TN, and by Aurobindo Pharma Limited, India. The label includes storage instructions and contact information for medication guides.*

FDA Label Image

Package Label-principal Display Panel – 800 mg (100 Tablets Bottle) (Gabapentin Fig7)

Label for Gabapentin Tablets, USP 800 mg oral film-coated tablets by NorthStar Rx LLC. The label states the product contains 100 tablets and includes storage information, manufacturer details, and contact information for medication guides. It features the NorthStar logo and is primarily printed in blue and black ink.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of gabapentin showing its cyclohexane ring with attached amino and carboxyl groups as the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.